Swedish Orphan Biovitrum AB (SOBI) AI Stock Analysis

• Market Cap: kr109.32B
• Dividend Yield: N/A
• Average Volume (3M): 396.16K
• Price to Earnings (P/E): 4452.2
• Beta (1Y): 1.14
• Revenue Growth: 9.50%
• EPS Growth: -99.31%
• Country: SE
• Employees: 1,895
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -8.32
• Shares Outstanding: 357,412,840
• 10 Day Avg. Volume: 356,894
• 30 Day Avg. Volume: 396,160
• PEG Ratio: 0.53
• Price to Book (P/B): 2.69
• Price to Sales (P/S): 4.17
• P/FCF Ratio: 24.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr368.33
• Price Target Upside: 12.92% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: kr374.00 ▲(14.65% Upside)

Swedish Orphan Biovitrum AB's overall stock score is driven primarily by its strong financial performance and positive technical indicators. However, the extremely high P/E ratio raises concerns about overvaluation, which significantly impacts the overall score. The absence of earnings call data and notable corporate events means these factors do not influence the score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion.

Cash Flow Generation

Strong cash flow generation supports operational stability and provides resources for reinvestment and growth opportunities.

Balance Sheet Health

Prudent leverage management enhances financial flexibility and reduces risk, supporting long-term sustainability.

Negative Factors

Low Net Profit Margin

A low net profit margin suggests potential inefficiencies or high costs, which could limit profitability and growth potential.

Earnings Conversion

Challenges in converting earnings to cash may impact liquidity and the ability to fund future initiatives or debt obligations.

EPS Growth Decline

A significant decline in EPS growth indicates potential earnings volatility, which may affect investor confidence and valuation.

Swedish Orphan Biovitrum AB Business Overview & Revenue Model

Company Description

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

How the Company Makes Money

SOBI generates revenue primarily through the sale of its innovative biopharmaceutical products. The company has a diverse range of therapies, including those for hemophilia and rare inflammatory diseases, which are sold to healthcare providers and hospitals. Key revenue streams include direct sales from its proprietary products, royalties from licensing agreements, and collaborations with other pharmaceutical companies that may involve co-development or marketing of therapies. SOBI also benefits from partnerships that expand its product pipeline and market presence, contributing significant revenue through shared resources and risk mitigation in drug development.

Swedish Orphan Biovitrum AB Financial Statement Overview

Summary

Swedish Orphan Biovitrum AB exhibits strong financial health with consistent revenue growth and solid margins. The balance sheet reflects prudent leverage and a strong equity position, while cash flow generation is robust, supporting future growth and stability. However, the low net profit margin indicates potential areas for cost optimization.

Income Statement

Swedish Orphan Biovitrum AB demonstrates strong revenue growth with a 3.27% increase in TTM, supported by solid gross and EBIT margins of 78.29% and 22.50% respectively. However, the net profit margin is relatively low at 0.16%, indicating potential cost management issues or one-time expenses impacting net income.

Balance Sheet

The company maintains a healthy debt-to-equity ratio of 0.33, showcasing prudent leverage management. Return on equity is moderate at 11.25%, reflecting efficient use of equity to generate profits. The equity ratio stands at 53.73%, indicating a strong equity base relative to total assets.

Cash Flow

Operating cash flow is robust, with a coverage ratio of 0.55, indicating good cash generation relative to net income. Free cash flow growth is impressive at 69.13%, although the free cash flow to net income ratio of 0.60 suggests room for improvement in converting earnings to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	71.26B	26.03B	22.12B	18.79B	15.53B	15.26B
Gross Profit	26.05B	20.24B	17.13B	14.01B	12.04B	12.04B
EBITDA	28.20B	9.30B	7.23B	6.05B	5.71B	6.73B
Net Income	-5.76B	3.88B	2.41B	2.64B	2.68B	3.25B
Balance Sheet
Total Assets	66.96B	75.44B	74.03B	52.50B	48.66B	48.28B
Cash, Cash Equivalents and Short-Term Investments	1.04B	1.14B	904.00M	1.36B	1.04B	404.00M
Total Debt	13.59B	16.73B	20.48B	9.10B	10.91B	14.57B
Total Liabilities	30.98B	35.15B	40.16B	25.97B	25.46B	28.08B
Stockholders Equity	35.98B	40.29B	33.87B	26.52B	23.20B	20.21B
Cash Flow
Free Cash Flow	17.43B	4.38B	-473.00M	3.19B	5.10B	1.36B
Operating Cash Flow	18.44B	7.39B	4.47B	4.67B	5.47B	5.21B
Investing Cash Flow	-12.03B	-3.09B	-21.90B	-1.48B	-367.00M	-3.96B
Financing Cash Flow	-5.43B	-4.00B	17.01B	-2.99B	-4.47B	-1.57B

Swedish Orphan Biovitrum AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 326.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SOBI, the sentiment is Neutral. The current price of 326.2 is below the 20-day moving average (MA) of 334.61, below the 50-day MA of 326.53, and above the 200-day MA of 295.49, indicating a neutral trend. The MACD of -0.64 indicates Positive momentum. The RSI at 39.30 is Neutral, neither overbought nor oversold. The STOCH value of 20.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:SOBI.

Swedish Orphan Biovitrum AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SOBI	69 Neutral	kr109.32B	4,452.25	11.60%	―	9.50%	-99.31%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NANEXA	50 Neutral	€483.96M	-11.75	-48.65%	―	-60.33%	58.04%
ORX	47 Neutral	kr836.79M	-4.18	―	―	-8.79%	-91.09%
ALZCUR	47 Neutral	kr247.07M	―	-90.66%	―	―	15.74%
KLAR	41 Neutral	€168.25M	-2.32	-530.21%	―	―	17.42%

Swedish Orphan Biovitrum AB Corporate Events

Helena Saxon Resigns from Sobi Board of Directors

Swedish Orphan Biovitrum AB (Sobi) announced the resignation of Helena Saxon from its Board of Directors, effective immediately, as she is set to join the board of another healthcare company. Saxon’s departure marks the end of her significant contributions to Sobi’s strategic development since 2011, as acknowledged by Sobi Chairman David Meek.

Sobi Reports Strong Q3 2025 Growth and Strategic Portfolio Expansion

Sobi reported accelerated growth in Q3 2025, with a 21% increase in revenue at constant exchange rates, driven by strong performance in its haematology and immunology segments. The company highlighted significant progress in its strategic portfolio, including the US filing acceptance for NASP in uncontrolled gout and EU approval for Tryngolza in severe hypertriglyceridemia. Despite a substantial impairment charge for Vonjo, Sobi remains optimistic about its long-term growth potential, with several new product launches anticipated to further strengthen its market position.

Sobi Revises 2025 Outlook Following Strong Q3 Performance

Sobi has revised its full-year outlook for 2025, anticipating revenue growth in the low double digits and an adjusted EBITA margin in the mid-to-high 30s percentage. This adjustment follows a strong Q3 performance, with a 21% revenue increase driven by products like Altuvoct, Doptelet, and Gamifant, and disciplined cost control. Additionally, Sobi recorded a non-cash impairment charge for Vonjo but continues to see it as a long-term growth driver. The company also announced the approval of Tryngolza for familial chylomicronaemia syndrome in Europe, highlighting a significant market potential.

Sobi Increases Common Shares and Votes

Swedish Orphan Biovitrum AB (Sobi) announced an increase in its total number of common shares and votes to 357,412,837 as of September 30, 2025, following the conversion of 1,412,788 class C shares to common shares. This change is part of Sobi’s efforts to fulfill commitments under its long-term incentive programs, potentially impacting its market operations and stakeholder interests.